Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals (JNP) to Discuss Second Quarter 2015 Results on August 4th Conference Call

BOSTON, July 21, 2015 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company") will hold a conference call on August 4, 2015, to discuss financial results of the second quarter ended June 30, 2015.  The call details are as follows:


Tuesday, August 4, 2015


8:30 AM EDT

Dial-in numbers:

Toll free: (866) 374-4635 (U.S.), (855) 669-9657 (Canada), or

International: (412) 902-4218

Webcast (live & archive):, under 'Investor' or click here

The teleconference replay will be available approximately one hour after completion through Friday, August 21, 2015, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10069118.  The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (formerly Columbia Laboratories) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health.  Juniper has a successful heritage in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck Serono S.A. in over 60 countries worldwide. The Company is leveraging in-house pharmaceutical development, clinical trial manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing valuable consultative services to its pharmaceutical industry customers. Please visit for more information.

Juniper Pharmaceuticals™ and Juniper Pharma Services™ are trademarks of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Allergan, Inc. in the U.S.

Katja Buhrer, MBS Value Partners
(212) 661-7004

Follow us on LinkedIn: 

Juniper Pharmaceuticals, Inc.



To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.